Corbus Pharmaceuticals Holdings Inc
CRBPLatest QuantConomy context for CRBP: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
Asset class
stock
Primary venue
NASDAQ
Recent signals
1
SEC filings
20
Asset profile
Corbus Pharmaceuticals Holdings Inc
QuantConomy has a structured record for CRBP. More descriptive asset metadata will appear here when the platform record includes it.
- Symbol
- CRBP
- Name
- Corbus Pharmaceuticals Holdings Inc
- Coverage
- 3 market/data records
- Sources
- alpaca fmp alphavantage
Latest signal rows
Recent signals for CRBP
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| events | bullish | 47 | Dec 11, 01:26 PM | NASDAQ reports positive developments for CRBP — in Corporate Crypto Adoptions / Corporate Structure and Governance Events / Corporate Events / Events — "Corbus Reports Positive Phase 1a Results Of CRB-913 In Obesity, Stock Surges - Update" — [weak signal from moderate source] |
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| CRBP | NASDAQ | alpaca | Corbus Pharmaceuticals Holdings, Inc. Common Stock |
| CRBP | NASDAQ | fmp | Corbus Pharmaceuticals Holdings, Inc. |
| CRBP | NASDAQ | alphavantage | Corbus Pharmaceuticals Holdings Inc |
Recent insider transactions
Buys, last 90d
1
Sells, last 90d
3
Rows
20
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | Kung Winston | Director | sale | 2,026 | $7.91 | $16,033 | 4 on EDGAR |
| Jun 10, 2026 | Jenkins John Kenneth | Director | sale | 4,800 | $7.91 | $37,986 | 4 on EDGAR |
| Jun 10, 2026 | Altmeyer Anne | Director | sale | 2,412 | $7.91 | $19,088 | 4 on EDGAR |
| Jun 2, 2026 | Saxena Nishant C | Chief Business Officer | purchase | 4,500 | $7.33 | $32,999 | 4 on EDGAR |
| — | Saxena Nishant C | Chief Business Officer | — | — | — | — | 3 on EDGAR |
| May 21, 2026 | Saxena Nishant C | Chief Business Officer | grant | 58,300 | $0.00 | $0 | 4 on EDGAR |
| May 19, 2026 | Pfeiffenberger Brent | Director | grant | 7,500 | $0.00 | $0 | 4 on EDGAR |
| May 19, 2026 | Jacques Rachelle Suzanne | Director | grant | 3,800 | $0.00 | $0 | 4 on EDGAR |
| May 19, 2026 | Kung Winston | Director | grant | 3,800 | $0.00 | $0 | 4 on EDGAR |
| May 19, 2026 | Jenkins John Kenneth | Director | grant | 3,800 | $0.00 | $0 | 4 on EDGAR |
| May 19, 2026 | Altmeyer Anne | Director | grant | 3,800 | $0.00 | $0 | 4 on EDGAR |
| May 19, 2026 | Ben Yong | Director | grant | 3,800 | $0.00 | $0 | 4 on EDGAR |
| Mar 2, 2026 | Smethurst Dominic | Chief Medical Officer | sale | 6,097 | $8.30 | $50,601 | 4 on EDGAR |
| Feb 3, 2026 | Hodgson Ian | Chief Operating Officer | sale | 2,415 | $8.09 | $19,537 | 4 on EDGAR |
| Feb 3, 2026 | Smethurst Dominic | Chief Medical Officer | sale | 3,285 | $8.09 | $26,575 | 4 on EDGAR |
| Jan 14, 2026 | Cohen Yuval | Chief Executive Officer | grant | 50,000 | $0.00 | $0 | 4 on EDGAR |
| Jan 14, 2026 | Smethurst Dominic | Chief Medical Officer | grant | 28,365 | $0.00 | $0 | 4 on EDGAR |
| Jan 14, 2026 | Hodgson Ian | Chief Operating Officer | grant | 28,365 | $0.00 | $0 | 4 on EDGAR |
| Jan 14, 2026 | Moran Sean F. | Chief Financial Officer | grant | 28,082 | $0.00 | $0 | 4 on EDGAR |
| Dec 11, 2025 | Cormorant Asset Management, LP | Insider | sale | 30,029 | $11.46 | $344,012 | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Get the data
Query CRBP context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access